Iambic Therapeutics company information, Employees & Contact Information

Revolution lines up Iambic's AI platform in discovery collab worth up to $25M Fierce Biotech

Iambic and Revolution Medicines Partner on AI Cancer Drug Discovery Genetic Engineering and Biotechnology News

Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs BioSpace

Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer Yahoo Finance

Revolution Medicines and Iambic Announce Technology and GlobeNewswire

Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors Business Wire

Revolution Medicines and Iambic Therapeutics Announce Collaboration to Explore Novel Drug Candidates Using Advanced AI Models Quiver Quantitative

Revolution Medicines partners with Iambic for AI-driven drug discovery Investing.com

Iambic debuts next version of AI model Enchant, driving new way for drug R&D Endpoints News

Iambic Therapeutics upgrades AI platform to fast-track promising drug candidates FirstWord Pharma

Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress Yahoo Finance

Iambic Named to CNBC’s 2025 Disruptor 50 List FinancialContent

Nvidia-backed AI firm Iambic unveils drug discovery ‘breakthrough’ Reuters

Iambic Therapeutics Appoints Peter Olson, Ph.D. as Chief Scientific Officer citybiz

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins BioSpace

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board Business Wire

Deal roundup: Novartis gets option to Sironax's neuro platform, plus Revolution and Iambic, Sernova and Eledon FirstWord Pharma

Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer Business Wire

Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference Business Wire

Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery Business Wire

Iambic and NVIDIA: Using AI to chart a faster course for drug discovery drugdiscoverytrends.com

Endpoints 11 winner Iambic Therapeutics: Entering the ‘show-me’ era for AI Endpoints News

Iambic ups rhythm in AI-enabled race to clinic, revealing $100M round and Nvidia pact Fierce Biotech

Lundbeck joins forces with Iambic to leverage AI for drug discovery The Pharma Letter

Iambic Therapeutics and NVIDIA partner to slash cancer drug development timelines drugdiscoverytrends.com

Iambic pockets another $50M to move its AI-discovered pipeline forward FirstWord Pharma

Iambic Therapeutics Announces "Enchant," an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery Yahoo Finance

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers Genetic Engineering and Biotechnology News

Wilson Sonsini Advises Iambic Therapeutics on $50 Million Series B Extension, Bringing Total Series B Funding to Over $150 Million Wilson Sonsini

Iambic Therapeutics Unveils Advances in AI Platform to Streamline Drug Discovery SynBioBeta

Iambic Moves into New HQ San Diego Business Journal

In its first clinical readout, Iambic shows early promise for AI-designed cancer drug Endpoints News

Iambic Raises $150 Million Series B San Diego Business Journal

Iambic begins dosing in trial of IAM1363 for HER2-driven cancer Clinical Trials Arena

26. Iambic Therapeutics CNBC

Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer Yahoo Finance

Iambic Therapeutics' AI-discovered cancer drug shows promise in early-stage trial Yahoo

Already Partnered With Nvidia, Iambic Adds $100M for AI Drug Discovery MedCity News

Iambic Nets $100M Series B San Diego Business Journal

Iambic Therapeutics Expands Leadership Team With the Appointment of Neil Josephson, MD as Chief Medical Officer BioSpace

Scale AI training and inference for drug discovery through Amazon EKS and Karpenter Amazon Web Services

Iambic Steps Ahead With $1M Grant to Scale AI Sneaker Fit Sourcing Journal

U.S. Support to the ICC (in AI-Generated Iambic Pentameter) Lieber Institute West Point